345 related articles for article (PubMed ID: 12615670)
1. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
[TBL] [Abstract][Full Text] [Related]
2. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
[TBL] [Abstract][Full Text] [Related]
6. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
[TBL] [Abstract][Full Text] [Related]
7. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
10. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Korsheninnikova E; Funahashi T; Matsuzawa Y; Nyman T; Yki-Järvinen H
J Clin Endocrinol Metab; 2003 Apr; 88(4):1907-10. PubMed ID: 12679491
[TBL] [Abstract][Full Text] [Related]
11. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.
Johnson JA; Albu JB; Engelson ES; Fried SK; Inada Y; Ionescu G; Kotler DP
Am J Physiol Endocrinol Metab; 2004 Feb; 286(2):E261-71. PubMed ID: 14532165
[TBL] [Abstract][Full Text] [Related]
12. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
[TBL] [Abstract][Full Text] [Related]
13. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity.
Kolak M; Westerbacka J; Velagapudi VR; Wågsäter D; Yetukuri L; Makkonen J; Rissanen A; Häkkinen AM; Lindell M; Bergholm R; Hamsten A; Eriksson P; Fisher RM; Oresic M; Yki-Järvinen H
Diabetes; 2007 Aug; 56(8):1960-8. PubMed ID: 17620421
[TBL] [Abstract][Full Text] [Related]
14. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
AIDS; 2002 Nov; 16(16):2183-93. PubMed ID: 12409740
[TBL] [Abstract][Full Text] [Related]
15. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy.
Cossarizza A; Riva A; Pinti M; Ammannato S; Fedeli P; Mussini C; Esposito R; Galli M
Antivir Ther; 2003 Aug; 8(4):315-21. PubMed ID: 14518701
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
Mavri A; Alessi MC; Bastelica D; Geel-Georgelin O; Fina F; Sentocnik JT; Stegnar M; Juhan-Vague I
Diabetologia; 2001 Nov; 44(11):2025-31. PubMed ID: 11719834
[TBL] [Abstract][Full Text] [Related]
17. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
18. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients.
Jan V; Cervera P; Maachi M; Baudrimont M; Kim M; Vidal H; Girard PM; Levan P; Rozenbaum W; Lombès A; Capeau J; Bastard JP
Antivir Ther; 2004 Aug; 9(4):555-64. PubMed ID: 15456087
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
20. Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution.
Andersen O; Pedersen SB; Svenstrup B; Hansen BR; Paulsen SK; Rathje GS; Richelsen B; Nielsen JO; Madsbad S; Iversen J; Haugaard SB
Clin Endocrinol (Oxf); 2007 Aug; 67(2):250-8. PubMed ID: 17524033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
